key: cord-0695367-jlerpd6i
authors: Silverberg, Jonathan I.; Zyskind, Israel; Naiditch, Hiam; Zimmerman, Jason; Glatt, Aaron E.; Pinter, Abraham; Theel, Elitza S.; Joyner, Michael J.; Hill, D. Ashley; Lieberman, Miriam R.; Bigajer, Elliot; Stok, Daniel; Frank, Elliot; Rosenberg, Avi Z.
title: Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study
date: 2021-07-15
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.06.046
sha: 8a0cf7bedd4b74ce197fa8cb3be276d86c4de04b
doc_id: 695367
cord_uid: jlerpd6i

Background The complex relationship between clinical manifestations of SARS-CoV-2 and individual immune responses is not fully elucidated. Objective To examine phenotypes of symptomatology and their relationship with positive anti-SARS-CoV-2 IgG antibody responses. Methods An observational study was performed of adults (≥18 years) from 5 US states. Participants completed an electronic survey and underwent testing to anti-SARS-CoV-2 nucleocapsid protein IgG antibody between May-July 2020. Latent Class Analysis was used to identify characteristic symptom clusters. Results Overall, 9,507 adults (mean±SD age: 39.6±15.0 years) completed the survey; 6,665 (70.1%) underwent antibody testing for anti-SARS-CoV-2 IgG. Positive SARS-CoV-2 antibodies were associated with self-reported positive SARS-CoV-2 nasal swab (bivariable logistic regression; OR [CI95]: 5.98 [4.83, 7.41]), household with ≥6 members (1.27 [1.14, 1.41]) and sick contact (3.65 [3.19, 4.17]), and older age (50-69 years: 1.55 [1.37, 1.76]); ≥70 years: 1.52 [1.16, 1.99]), but inversely associated with female sex (0.61 [0.55, 0.68]). Latent class analysis revealed 8 latent classes of symptoms. Latent classes-1 (all symptoms) and 4 (fever, cough, muscle ache, anosmia, dysgeusia, and headache) were associated with the highest proportion (62.0% and 57.4%) of positive antibodies, whereas classes-6 (fever, cough, muscle ache, headache) and 8 (anosmia, dysgeusia) had intermediate proportions (48.2% and 40.5%), and classes-3 (headache, diarrhea, stomach pain) and 7 (no symptoms) had the lowest proportion (7.8% and 8.5%) of positive antibodies. Conclusion SARS-CoV-2 infections manifest with substantial diversity of symptoms, which are associated with variable anti-SARS-CoV-2 IgG antibody responses. Prolonged fever, anosmia and receiving supplemental oxygen therapy had strongest associations with positive SARS-CoV-2 IgG.

SARS-CoV-2 infection induces variable humoral immune responses. While most patients with COVID-19 develop SARS-CoV-2 IgA, IgM and IgG antibodies over days and weeks following infection, target antigens and quantitative titers can vary 1 . The importance of antibody titers was demonstrated in two recent studies. One study showed an inverse correlation between IgG levels and persistence of viral shedding 2 . Another study showed a dose-dependent relationship between titers of anti-SARS-CoV-2 spike-protein IgG in transfused convalescent plasma and patient survival in COVID-19 3 . Assay-and antibody-dependent factors may impact antibody measurements and their use in determining individual immunity or population-level seroprevalence 4, 5 . Importantly, such levels may also correlate with patient characteristics such as age and severity of illness in hospitalized patients 2, 6 .

Little is known about the clinical and demographic predictors of positive anti-SARS-CoV-2 IgG antibody responses in patients with mild SARS-CoV-2 infections. We hypothesize that age, sex, and symptom severity among other factors impact the strength of anti-SARS-CoV-2 nucleocapsid protein IgG antibody response. In addition, symptoms of COVID-19 exhibit substantial variation 7, 8 . The significance of such variation is unclear, particularly as it relates to variation in anti-SARS-CoV-2 IgG antibody responses. We additionally hypothesize that specific phenotypes of SARS-CoV-2 symptoms are predictors of IgG antibody responses to SARS-CoV-2 nucleocapsid protein. In this large-scale study we examine the diversity of SARS-CoV-2 symptomatology and its relationship to IgG antibody responses in a convalesced population with a high SARS-CoV-2 seroprevalence.

The study involved a two-stage sampling design as previously described 9 . Stage 1 was designed to determine the self-reported symptoms and outcomes of SARS-CoV-2 in adults.

Subjects were recruited by local not-for-profit and social service organizations within orthodox Jewish communities across five states (California, Connecticut, Michigan, New Jersey, New York) between May 13 and July 6, 2020. A cross-sectional survey invitation was sent to adults; 12, 626 individuals began the survey process, with 9,507 adults completing the survey (completion rate=75.4%). In stage 2, a subset of 6,665 adults (70.1% response rate) had antibody testing performed shortly after completing the survey. Electronic informed consent and disclosure of the study purpose was performed prior to beginning the survey. The study was open to all participants and did not require participants to have SARS-CoV-2 symptoms or exposures in order to participate. The study was approved by IntegReview institutional review board.

The survey was developed to determine the most common symptoms and outcomes of SARS-CoV-2 (Online Repository Text). The survey included 81 data points including questions about patient demographics, contacts with other Covid-19 infected individuals in the household, symptoms of SARS-Cov-2, whether they tested positive for SARS-CoV-2 by nasal swab (yes/no), and required oxygen for SARS-CoV-2 throughout their illness. The survey was administered via the HIPPA-compliant and secure Research Data Capture (REDCap) software.

Anti-SARS-CoV-2 antibody measurements were performed at the Mayo Clinic Laboratory (Rochester, MN) using the Epitope Diagnostics (EDI) ELISA (San Diego, CA), established and used for clinical reporting of qualitative test for detection of IgM or IgG antibodies to the nucleocapsid protein from SARS-CoV-2. For the purposes of this study, IgG J o u r n a l P r e -p r o o f results were reported as described previously, with index value thresholds of ≥1.21, ≤1.01, and 1.01-1.20 for positive, negative, and indeterminate results 10 .

Baseline characteristics were determined and summary statistics were estimated.

Frequency and proportion of SARS-CoV-2 symptoms were estimated overall and in those with positive SARS-CoV-2 antibodies.

Latent class analysis (LCA) was used to examine phenotypical patterns of SARS-CoV-2 symptoms. LCA uses observed categorical or binary data to identify patterns, or latent classes.

Conditional probabilities were estimated using maximum likelihood to characterize the latent classes by indicating the chance that a member would give a certain response (yes/no) for the specific symptom. Conditional probability plots are presented, where probabilities closer to 0 or 1 indicate lower or higher chances, respectively. LCA regression models examine the differential effects of individual variables across unobserved classes. The ideal number of latent classes and best fitting models were selected by minimizing the Akaike's information criterion (CAIC) and Bayesian information criterion (BIC) and interpretability. Chi-square tests were used to test the associations of age, gender, household size (above or below the median household size) and the presence of sick contacts in the household with membership in the latent classes.

Among adults with positive SARS-CoV-2 antibodies, bivariable logistic regression models were constructed to determine whether demographic or household characteristics are associated with having at least one SARS-CoV-2 symptom or individual SARS-CoV-2 symptom (dependent variables). Crude odds ratio (OR) and 95% confidence intervals (CI) were estimated. Similarly, Poisson regression models were constructed to identify associations of the number of self-reported SARS-CoV-2 symptoms (dependent variable). Crude risk ratios (RR) and 95% CI were estimated. Multivariable models included sex (m/f), age (continuous), J o u r n a l P r e -p r o o f household size and number of household sick contacts. Adjusted OR, RR and 95% CI were estimated. Two-and three-way statistical interactions were tested between covariables.

Bivariable logistic regression models were also constructed to determine whether demographic or household characteristics, SARS-CoV-2 symptoms, and latent classes of SARS-CoV-2 symptoms are associated with having positive SARS-CoV-2 antibody tests (binary dependent variables). OR and 95% CI were estimated. Multivariable models included all variables from the bivariable models (except for self-report of any symptoms or fever) and state of residence. Adjusted OR and 95% CI were estimated. Two-and three-way statistical interactions were tested between covariables.

Bivariable logistic regression models were constructed to elucidate the impact of household size overall, and number of children age 0-3, 4-10 or 11-17 years (independent variables) on positive SARS-CoV-2 antibodies (binary dependent variable). Multivariable models controlled for age, sex and state of residence.

All data processing and statistical analyses were performed in SAS version 9.4.3 (SAS Institute, Cary, NC, USA). Complete data analysis was performed, i.e. subjects with missing data were excluded. A two-sided p-value <0.05 was considered statistically significant.

J o u r n a l P r e -p r o o f

The survey cohort had a median (interquartile range [ 

Among respondents with positive SARS-CoV-2 antibodies, 178 (8.9%) reported no SARS-CoV-2 symptoms. Self-report of any SARS-CoV-2 symptoms was associated with households with ≥6 members (bivariable logistic regression; OR [95% CI]: 1.63 [1.20, 2.22]) or a sick contact (6.50 [4.55, 9. 28]), and reporting a positive SARS-CoV-2 nasal swab test (5.41 [2.37, 12.32] ). In multivariable models, significant associations were observed for age 50-69 years, household sick contacts, and having a positive SARS-CoV-2 nasal swab test (Table E2) . Similarly, the number of self-reported SARS-CoV-2 symptoms was associated with female sex (Table E3 ). In multivariable models, the associations remained significant for age ≥70 years, female sex, household sick contacts and having a positive COVID nasal swab. There were no significant two-or three-way statistical interactions.

To identify statistically significant homogeneous patterns of SARS-CoV-2 symptoms (Table 3) . Class-2 had the next highest membership probability (18.8% of the survey cohort) and had higher probabilities of muscle ache and headache. Class-4 (17.8% of the survey cohort) had higher probabilities of fever, cough, muscle ache, anosmia, dysgeusia, and headache. Class-6 (15.0% of the survey cohort) had higher probabilities of fever, cough, muscle ache, and headache. Class-1 (6.2% of the survey cohort) had higher probabilities of all symptoms. Class-8 (5.9% of the survey cohort) had higher probability of anosmia and dysgeusia. Class-5 (5.4% of the survey cohort) had higher probabilities of fever, cough, muscle ache, headache, diarrhea, and stomach pain. Class-3 (3.7% of the survey cohort) had higher probabilities of headache, diarrhea, and stomach pain.

There were significant associations of latent class membership with age, gender, household size and the presence of sick contacts in the household (Chi-square, P<0.0001 for all) ( Figure 1B ). Membership in Classes-6 and 7 was highest in older age, whereas Classes-1, 2, 4 and 8 were highest in younger age. Class-2 membership was highest in females, whereas J o u r n a l P r e -p r o o f Classes-4, 6 and 8 were higher in males. Membership in Classes-1, 4 and 8 were highest in household with ≥6 members, whereas Class-7 was highest in household with 5 members.

Membership in Classes-1, 4, 5, 6 and 8 were highest in households with a sick contact, whereas membership in Classes-2, 3 and 7 were highest in households with no sick contacts.

Positive SARS-CoV-2 antibodies were associated with positive SARS-CoV-2 nasal swab Table   1 ). The associations remained significant in multivariable regression models.

Multivariable regression models were constructed to determine whether presence of Table 2 ). These associations remained significant in multivariable models controlling for age, sex and state of residence.

The symptom most strongly associated with positive SARS-CoV-2 antibodies was fever ( Finally, latent classes-1 (all symptoms) and 4 (fever, cough, muscle ache, anosmia, dysgeusia, and headache) were associated with the highest proportion (62.0% and 57.4%) with positive antibodies, whereas Classes-6 (fever, cough, muscle ache, headache) and 8 (anosmia, dysgeusia) were associated with intermediate proportions (48.2% and 40.5%), and Classes-3 (headache, diarrhea, stomach pain) and 7 (no symptoms) had the lowest proportion (7.8% and 8.5%) of positive SARS-CoV-2 IgG antibody tests (Table 3 ). There were no significant two-or three-way statistical interactions in any of the abovementioned multivariable models.

In this large-scale observational cohort, we demonstrate substantial diversity of symptoms from SARS-CoV-2 infection. The five most common symptoms reported in the survey cohort were headache, myalgia, cough, anosmia and fever. Whereas, in serologically-confirmed COVID-19 patients, the most common symptoms were similarly myalgia, headache, cough, anosmia, and fever. Certain clinical characteristics have particularly strong relationships with anti-SARS-CoV-2 IgG antibody response, including prolonged fever, anosmia and receiving supplemental oxygen therapy, which is consistent with prior reports 11 .

We employed LCA to further elucidate the COVID symptom complex and its relationship with IgG antibody responses. LCA is a statistical method used to identify a set of discrete subgroups or latent classes of individuals based on their responses to a set of categorical variables 12 . Adults who experienced all symptoms (Class 1) and those who specifically had fever, cough, muscle ache, anosmia, dysgeusia, and headache (Class 4) were most likely to have positive anti-SARS-CoV-2 antibodies and self-reported SARS-CoV-2 polymerase chain reaction (PCR) nasal swabs. Interestingly, anosmia and dysgeusia alone (Class 8) were not associated with as robust an immune response as fever, cough, muscle ache and headache (Class 6). This appears to be in contrast to a prior study in healthcare workers, and may suggest an association with a more robust immunophenotype with Class 6 13 . Similar to a prior study 14 , we found that headache was reported in all but two latent-classes (7 and 8). These symptom patterns may be useful to predict the likelihood of having SARS-CoV-2 infection and related outcomes based on symptoms alone, and potentially guide occupational and public health recommendations regarding resource allocation. In addition, these symptom patterns can help predict which patients likely have positive IgG antibodies to SARS-CoV-2 and guide clinical recommendations regarding vaccination and social distancing requirements.

We found that households with more than 5 residents had more SARS-Cov-2 symptoms and positive antibodies in bivariable analyses. These associations were attenuated after J o u r n a l P r e -p r o o f controlling for sick contacts in multivariable models. That is, people living in larger households have more potential sick contacts during an outbreak. In particular, the presence of adolescents was associated with higher antibody positivity, but not younger children. These results have important ramifications for public health and school policy. First, socio-cultural groups with more persons per household may be prone to higher rates of infections. Second, households with more persons, particularly adolescents, may warrant more caution with respect to mitigation strategies for preventing community-based spread of SARS-Cov-2 infection. Third, as schools and workplaces around the world develop policies to reopen in-person, it is important to distinguish between regions and socio-cultural groups with typically larger vs. smaller household sizes. Adolescents and adults who might become infected with SARS-CoV-2 in school and work, can transmit the virus to far more people residing in a larger vs. smaller households, thereby potentially increasing community spread.

Strengths of this study include the large sample size, inclusion of a wide age-range and spectrum of disease severity, including a fairly high proportion of younger adults and milder symptoms. This allowed for comparison of symptoms and IgG antibody responses as a function of age and symptom severity. However, there are limitations. This ambulatory cohort may not accurately reflect the symptomatology and serologic profiles of patients with more severe disease. Viral PCR positivity was assessed via survey rather than direct testing. Moreover, this cohort included persons from communities with early COVID-19 outbreaks, when PCR testing

was not yet widely accessible across the US. Many participants were unable to get PCR testing, leading to a low proportion (6%) who reported having a positive PCR test, i.e. patients who reported not having a positive PCR may not have been tested. Thus, it is possible that some participants who experienced COVID-19 symptoms had other viral illnesses. We analyzed antibodies to the nucleocapsid protein but not spike protein, which may have led to lower rates of antibody positivity. Data on travel history and contact tracing were not available. This was a largely Ashkenazi Jewish population. COVID-19 hit the Orthodox Jewish community in the J o u r n a l P r e -p r o o f United States particularly hard, especially in the early days when much was unknown. At that time of great loss, Jewish communities around the United States rallied to participate in research to help the millions of other people impacted by the pandemic. While the cohort included broad representation of age and sex, there was limited racial diversity. It is additionally unclear whether seroconversion using currently available assays reflects immunity to SARS-CoV-2, especially as the absence of T-cell data in a large portion of our population overlooks a phenotype of immunity that may be especially important in asymptomatic patients 15, 16 . This latter aspect regarding cellular immunity patterns is an aspect that we are following up in future studies.

In conclusion, SARS-CoV-2 was associated with a heterogeneous profile of symptoms. J o u r n a l P r e -p r o o f Bivariable logistic regression models were constructed with SARS-CoV-2 IgG test results (positive vs. negative/indeterminate) as the dependent variable and presence of children ages 0-3, 4-10, or 11-17 years (0, ≥1), and number of other adults in the household (0, 1, 2-5, >5). Crude odds ratios (OR) and 95% confidence intervals (CI) were estimated. Multivariable regression models included age (continuous) and sex (male, female) as fixed-effects variables, and state of residence. Adjusted OR and 95% CI were estimated. The age cutoffs were selected a priori based on previous reports suggesting that younger children are least likely to transmit COVID, followed by older children, then adolescents and greatest transmission occurring in adults 17, 18 .

J o u r n a l P r e -p r o o f 

J o u r n a l P r e -p r o o f

Analyses were limited to adults with positive SARS-CoV-2 IgG test results. Bivariable logistic regression models were constructed with any SARS-CoV-2 symptoms (yes vs. no) as the dependent variable and age, sex, household size, household sick contacts, and self-report of a positive SARS-CoV-2 nasal swab test as the independent variables. Crude odds ratios (OR) and 95% confidence intervals (CI) were estimated. Multivariable regression models included all variables from the bivariable models, and state of residence. Adjusted OR and 95% CI were estimated. Thank you for participating in this COVID antibody drive and CAPS research study.

As part of the registration process, you will need to fill out a survey about your COVID-19 symptoms, if any, that you experienced during the recent COVID outbreak. The survey should take between 5 and 10 minutes. After completing the survey, you will immediately be able to select a location and time for your antibody blood draw.

By agreeing to be part of this study, we will accomplish the following goals: 1) It will allow local doctors and community leaders to determine the true extent of the immune response in your neighborhood. We will be testing individuals who had COVID-19 symptoms (with or without a COVID-19 test) and well as those who never had any symptoms.

2) It will provide you with the most advanced and accurate antibody testing results that exist, utilizing the Mayo Clinic's testing platform.

3) It will allow for further study and analysis of our communities' antibody response by the National Institutes of Health (NIH). The NIH will utilize the results and the blood sample to create better COVID-19 tests and assist in the development of a vaccine.

The next section contains a link to an Informed Consent form that details the purpose of this study and asks for your permission to enroll, should you so wish. Please read it over and, if you agree, accept the consent.

We thank you for your time and consideration to help us with this vital matter.

Click on the link to view the Informed Consent form. Please review this consent to participate in this study. What is your last name?

What is your first name?

What is your email?

J o u r n a l P r e -p r o o f projectredcap.org 07/13/2020 11:57am 07/13/2020 11:57am 07/13/2020 11:57am 07/13/2020 11:57am None 1 day 2 days 3 days 4 days 5 days 6 days 7 days 8 days 9 days 10 or more days 

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

How can we interpret SARS-CoV-2 antibody test results? Pathog Dis

Dynamics and significance of the antibody response to SARS-CoV-2 infection

SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike

Identification of optimal symptom combinations to trigger diagnostic work-up of suspected COVID-19 cases: analysis from a community-based, prospective, observational cohort

The prevalence of symptoms in 24

COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries

SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United States

Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Latent class analysis: an alternative perspective on subgroup analysis in prevention and treatment

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Covid-19: Study reveals six clusters of symptoms that could be used as a clinical prediction tool

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders

Comparison of COVID-19 Incidence Rates Before and After School Reopening in Israel

Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany

Duration (days) -min -max

Within the cohort of patients who completed the SARS-CoV-2 survey, missing data were encountered in 1475 (15.5%) for age

2-1.4%) 2 for other symptoms, 319 (3.4%) for PCR testing, 176 (1.9%) for requirement of oxygen therapy, 187 (2.0%) for emergency 3 department visits

Within the cohort of patients who completed the SARS-CoV-2 survey and had antibody testing, missing data were encountered in 5 19 (0.3%) for age, 0 (0.0%) for sex, 27 (0.4%) for household size, 743 (11.4%) for household sick contacts, 0 (0.0%) for presence of 6 symptoms, 1 (0.01%) for any fever and peak fever, 2 (0.02%) for duration of fever, 1 for duration of fever (1.7%)

4%) for PCR testing, 21 (0.3%) for requirement of oxygen therapy, 21 (0.3%) for emergency department 8 visits, and 21 (0.3%) for inpatient hospitalizations

Similar rates of survey completion were observed across different age groups (97.4% for age 18-49 years, 98.3% for 50-69 years

J o u r n a l P r e -p r o o f